“Exciting Results Announced at SABCS”
by
Wayne Kuznar,
Contributing Writer
December 10, 2023
The combination of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) has shown promise in increasing progression-free survival (PFS) in patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, new data from the INAVO120 trial reveals.
Dr. Komal Jhaveri, from Memorial Sloan Kettering Cancer Center in New York City, says that in patients who recurred within 12 months of adjuvant endocrine therapy, the investigational selective PI3Kα inhibitor more than doubled the median PFS from 7.3 to 15 months. She presented these findings at a press briefing for the San Antonio Breast Cancer Symposium (SABCS).
The early data also suggests a possible improvement in overall survival (OS) with inavolisib as add-on therapy compared to a placebo, Jhaveri reported.
Jhaveri is optimistic about the trial findings, stating that the triplet therapy “may represent a new standard of care for patients with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer.
Inavolisib is an oral, highly potent and selective inhibitor of the PI3K catalytic subunit α isoform protein that also promotes the degradation of p110α. The trial revealed promise as the overall discontinuation rate for the drug was low.
Palbociclib, which was approved by the FDA in 2015, had its indications expanded in 2019, is also used to treat metastatic breast cancer. Inavolisib is a phase III, randomized, double-blind, placebo-controlled study which assessed, inavolisib combined with palbociclib plus fulvestrant or placebo in patients with PIK3CA-mutated HR-positive HER2-negative advanced breast cancer.
To read in more detail about this exciting development, click on the link below.
